The Procter Gamble Company

Precisionbiotics Group Limited

Alimentary Health Limited

Charles Carson Bascom

Deborah Ruth Finlay

Dean Larry DuVal

Ross Strand

Jun Xu

Liam Diarmuid O'Mahony

Raphael Warren

Yunming Shi

John McMillan McIver

John Erich Oblong

Duane Larry Charbonneau

David Joseph Eickhoff

Douwe Van Sinderen

Kevin John Mills

Raymond Alan Grant

Tomohiro Hakozaki

Robert Scott Youngquist

Rosemarie Osborne

Robert Joseph Isfort

Sara Johnson McPhail

Shannon Christine McArthur

Robert Lloyd Binder

Wenzhu Zhao

Miranda Aref Farage

David Burton Moore

Kenneth Robert Wehmeyer

Malgorzata Klukowska

Aaron Reed Biesbrock

Andrew W Fulmer

Gina Marie Fadayel

Wenzhu (Steven) Zhao

Heather Eileen Matheny

Song Yuli

Jay Patrick Tiesman

Yuli Song

Murray A Friedman

Liam O'mahony

Ryan Tasseff

Wenzhu Steven Zhao

Raymond A Grant

Human skin tissue sample methods and models for identifying and screening test agents as effective for providing skin tone benefits, methods for validating hypotheses for mechanisms driving skin pigmentation as well as methods for driving skin pigment levels in ex-vivo skin tissue. The method includes contacting a cultured human skin tissue sample with a test agent, generating a transcriptional profile from the sample, and comparing the results to a control to determine if the test agent is effective for providing a skin tone benefit.

Human skin sample methods and models for validating hypotheses for mechanisms driving skin pigmentation

The multiple embodiments described herein comprise the genome of a probioticbifidobacteria strain and genes encoded by the genome. Various novelare described.

Methods and systems for constructing a gene expression signature representative of a number of biological conditions, systems and methods for determining functional relationships between a skin-active agent and skin conditions of interest, and methods and systems for identifying skin-active agents with broad spectrum activity are provided.

Systems, models and methods for identifying and evaluating skin-active agents effective for treating an array of skin disorders

Provided are methods and systems for determining functional relationships between ex vivo skin models and an inflammatory skin condition. Also provided are methods and systems for identifying modulators of inflammation of skin, as well as the use of modulators identified by such methods or systems for the preparation of cosmetic compositions, personal care products, or both.

Human ex vivo skin model and its use in methods of identifying modulators of skin inflammation

Bifidobacterium longum

An array of methods for assessing vaginal atrophy are disclosed. The methods may be used alone or in combination with a treatment or as part of a kit.

Methods for assessing vaginal atrophy

A screening method for identifying an agent as effective for providing an anti-aging skin benefit is provided. The screening method includes culturing first and second human skin samples from about 3 days to about 19 days, wherein the first and second human skin samples are derived from a human skin surgical waste tissue. The first human skin sample is contacted with at least one test agent. The second human skin sample is contacted with a positive control. Transcriptional profiles are generated from the first and second human skin samples, and the at least one test agent is identified as effective for providing an anti-aging skin benefit when the transcriptional profiles of at least two genes show a similar directional change in comparison to one or more untreated control tissue samples.

Methods and models for assessing anti-aging benefits of agents

The present invention relates to a topical skin care composition containing a safe and effective amount of a skin care active comprising agmatine, and its salt; a safe and effective amount of a first additional skin care active selected from the group consisting of BHT or BHA, hexamidine, cetyl pyridinium chloride, green tea catechins, phytosterols, ursolic acid, compounds derived from plant extracts, their salts and derivatives; and a dermatologically acceptable carrier for the agmatine composition. The present invention also relates to methods of using such agmatine compositions to regulate hair growth and the condition of mammalian skin. The methods generally comprise the step of topically applying the composition to the skin of a mammal needing such treatment, a safe and effective amount of such compositions.

Inhibition of mammalian hair growth

The present invention relates to a topical skin care composition containing a safe and effective amount of a skin care active comprising agmatine, and its salt; a safe and effective amount of a first additional skin care active selected from the group consisting of BHT or BHA, hexamidine, cetyl pyridinium chloride, green tea catechins, phytosterols, ursolic acid, compounds derived from plant extracts, their salts and derivatives; and a dermatologically acceptable carrier for the agmatine composition. The present invention also relates to methods of using such agmatine compositions to regulate hair growth and the condition of mammalian skin. Said methods generally comprise the step of topically applying the composition to the skin of a mammal needing such treatment, a safe and effective amount of such compositions.

Regulation of mammalian hair growth

The present invention relates to topical compositions comprising a peptide having the formula

Compositions for treating wrinkles comprising a peptide

Growing community of inventors

Liberty Township, OH, United States of America

Charles Carson Bascom